Your browser doesn't support javascript.
loading
Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India.
Singh, Chandramani; Naik, Bijaya Nanda; Pandey, Sanjay; Biswas, Bijit; Pati, Binod Kumar; Verma, Manisha; Singh, Prabhat Kumar.
Afiliación
  • Singh C; Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
  • Naik BN; Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
  • Pandey S; Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
  • Biswas B; Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
  • Pati BK; Department of Microbiology, All India Institute of Medical Sciences, Patna, Bihar, India.
  • Verma M; Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
  • Singh PK; Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Patna, Bihar, India.
Epidemiol Infect ; 149: e224, 2021 10 11.
Article en En | MEDLINE | ID: mdl-34632972
ABSTRACT
Effectiveness of corona virus disease-19 (COVID-19) vaccines used in India is unexplored and need to be substantiated. The present case-control study was planned to elicit the effectiveness of COVID-19 vaccines in preventing infection and disease severity in the general population of Bihar, India. This case-control study was conducted among people aged ≥45 years during April to June 2021. The cases were the COVID-19 patients admitted or visited All India Institute of Medical Sciences (AIIMS), Patna, Bihar, India, and were contacted directly. The controls were the individuals tested negative for severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) at the Virology laboratory, AIIMS-Patna and contacted telephonically for collection of relevant information. The vaccine effectiveness (VE) was calculated by using the formula (VE = 1 - odds ratio). The adjusted VE for partial and full vaccination were estimated to be 52.0% (95% confidence interval (CI) 39.0-63.0%) and 83.0% (95% CI 73.0-89.0%) respectively for preventing SARS CoV-2 infection. The sub-group analyses of the cases have shown that the length of hospital stays (LOS) (partially vaccinated 9 days vs. unvaccinated 12 days; P = 0.028) and the severity of the disease (fully vaccinated 30.3% vs. partially vaccinated 51.3% and unvaccinated 54.1%; P = 0.035) were significantly low among vaccinated compared to unvaccinated individuals. To conclude, four out of every five fully vaccinated individuals are estimated to be protected from contracting SARS CoV-2 infection. Vaccination lowered LOS and chances of development of severe disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Epidemiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / EPIDEMIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Epidemiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / EPIDEMIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: India